主要文件

查看所有文档

SML0486

依克立达

Name: 依克立达
Brand: SIGMA

≥98% (HPLC), powder, ABC transporters MDR-1 (P-gp) inhibitor

别名:

GF120918, GG918, GW0918, N-[4-[2-（3,4-二氢-6,7-二甲氧基-2 (1H)-异喹啉基）乙基] 苯基]-9,10-二氢-5-甲氧基-9-氧代-4-吖啶甲酰胺

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₃₄H₃₃N₃O₅

化学文摘社编号:

143664-11-3

分子量:

563.64

UNSPSC Code:

12161501

PubChem Substance ID:

329825437

NACRES:

NA.77

MDL number:

MFCD00912604

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

产品名称

依克立达, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL (clear solution, warmed)

shipped in

wet ice

storage temp.

−20°C

SMILES string

COc1cccc2C(=O)c3cccc(C(=O)Nc4ccc(CCN5CCc6cc(OC)c(OC)cc6C5)cc4)c3Nc12

InChI

1S/C34H33N3O5/c1-40-28-9-5-7-26-32(28)36-31-25(33(26)38)6-4-8-27(31)34(39)35-24-12-10-21(11-13-24)14-16-37-17-15-22-18-29(41-2)30(42-3)19-23(22)20-37/h4-13,18-19H,14-17,20H2,1-3H3,(H,35,39)(H,36,38)

InChI key

OSFCMRGOZNQUSW-UHFFFAOYSA-N

说明

Application

依克立达（Elacridar）可用作：

作为化学物质，解释自噬作用与舒尼替尼耐药机制之间的联系
作为 ATP 结合盒 B亚家族1成员的抑制剂，研究其对 NSC23766细胞毒性的作用
处理罗丹明123（Rh123）标记细胞，在荧光激活细胞分选法（FACS）中设置分选门

Biochem/physiol Actions

GF120918（依克立达）是 ABC 转运蛋白 MDR-1 (P-gp) 和 BCRP 的强效抑制剂。GF120918 可增加细胞毒性抗肿瘤药物的生物利用度，也可导致大脑和 CNS 中抗 HIV 药物水平升高。

GF120918（依克立达）是一种 MDR-1 (P-gp) 抑制剂。

Features and Benefits

这种化合物是 ADME 毒性研究的特色产品。点击此处发现更多特色 ADME 毒性产品。在sigma.com/discover-bsm可了解更多关于生物活性小分子的其他研究领域。

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

0000516659

0000464197

0000424769

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

商品

Discover Bioactive Small Molecules for ADME/Tox

The influence of modulation of P-glycoprotein and /or cytochrome P450 3A on the pharmacokinetics and pharmacodynamics of orally administered morphine in dogs.

C Gadeyne et al.

Journal of veterinary pharmacology and therapeutics, 34(5), 417-423 (2011-01-19)

The influence of pretreatment with ketoconazole [cytochrome P450 3A (CYP3A) + P-glycoprotein (P-gp) inhibitor], elacridar (selective P-gp inhibitor) and rifampicin (CYP3A + P-gp inducer) on oral morphine pharmacokinetics and pharmacodynamics was investigated in experimental dogs. Seven beagles were used in

Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.

Selvi Durmus et al.

Molecular pharmaceutics, 9(11), 3236-3245 (2012-10-02)

Vemurafenib (PLX4032) is a novel tyrosine kinase inhibitor that has clinical efficacy against metastatic melanoma harboring a BRAF(V600E) mutation. We aimed to establish whether oral availability and brain penetration of vemurafenib could be restricted by the multidrug efflux transporters P-glycoprotein

Dual approach utilizing self microemulsifying technique and novel P-gp inhibitor for effective delivery of taxanes.

Akash Chaurasiya et al.

Journal of microencapsulation, 29(6), 583-595 (2012-03-24)

In the present work, concomitant use of self-microemulsifying drug delivery systems (SMEDDS) and a novel third-generation P-gp inhibitor, GF120918 (elacridar), for the effective transport of taxanes (paclitaxel and docetaxel) across an in vitro model of the intestinal epithelium and uptake into

查看所有相关文献

全球贸易项目编号

货号	GTIN
SML0486-10MG	04061837084652
SML0486-50MG	04061837084669